Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
32
ZLAB Quote, Financials, Valuation and Earnings
Last price:
$18.60
Seasonality move
:
1.52%
Day range:
$18.25 - $19.01
52-week range:
$16.82 - $44.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.51x
P/B ratio:
2.71x
Volume:
594.4K
Avg. volume:
884.3K
1-year change:
-30.9%
Market cap:
$2.1B
Revenue:
$399.2M
EPS (TTM):
-$1.95
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
ANL
Adlai Nortye Ltd.
|
-- | -$1.31 | -- | -33.06% | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$18.58 | $49.17 | $2.1B | -- | $0.00 | 0% | 4.51x |
|
ADAG
Adagene, Inc.
|
$1.85 | $9.22 | $87.2M | -- | $0.00 | 0% | 832.60x |
|
ANL
Adlai Nortye Ltd.
|
$1.55 | -- | $57.2M | -- | $0.00 | 0% | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.78 | $4.00 | $16.1M | -- | $0.00 | 0% | 0.46x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.31 | -- | $4.3M | -- | $0.00 | 0% | 1.06x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
ANL
Adlai Nortye Ltd.
|
-- | -0.956 | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
ANL
Adlai Nortye Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
Zai Lab Ltd. vs. Competitors
-
Which has Higher Returns ZLAB or ADAG?
Adagene, Inc. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -26.7% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About ZLAB or ADAG?
Zai Lab Ltd. has a consensus price target of $49.17, signalling upside risk potential of 164.64%. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 398.61%. Given that Adagene, Inc. has higher upside potential than Zai Lab Ltd., analysts believe Adagene, Inc. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 ADAGAdagene, Inc.6 2 0 -
Is ZLAB or ADAG More Risky?
Zai Lab Ltd. has a beta of 0.872, which suggesting that the stock is 12.778% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZLAB or ADAG?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or ADAG?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than Adagene, Inc. quarterly revenues of --. Zai Lab Ltd.'s net income of -$36M is higher than Adagene, Inc.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.51x versus 832.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.51x -- $116.2M -$36M ADAGAdagene, Inc.832.60x -- -- --
-
Which has Higher Returns ZLAB or ANL?
Adlai Nortye Ltd. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -26.7% beat Adlai Nortye Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M ANLAdlai Nortye Ltd.-- -- -- -
What do Analysts Say About ZLAB or ANL?
Zai Lab Ltd. has a consensus price target of $49.17, signalling upside risk potential of 164.64%. On the other hand Adlai Nortye Ltd. has an analysts' consensus of -- which suggests that it could grow by 492.11%. Given that Adlai Nortye Ltd. has higher upside potential than Zai Lab Ltd., analysts believe Adlai Nortye Ltd. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 ANLAdlai Nortye Ltd.0 1 0 -
Is ZLAB or ANL More Risky?
Zai Lab Ltd. has a beta of 0.872, which suggesting that the stock is 12.778% less volatile than S&P 500. In comparison Adlai Nortye Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZLAB or ANL?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adlai Nortye Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Adlai Nortye Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or ANL?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than Adlai Nortye Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$36M is higher than Adlai Nortye Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Adlai Nortye Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.51x versus -- for Adlai Nortye Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.51x -- $116.2M -$36M ANLAdlai Nortye Ltd.-- -- -- --
-
Which has Higher Returns ZLAB or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of -353.92%. Zai Lab Ltd.'s return on equity of -26.7% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About ZLAB or CASI?
Zai Lab Ltd. has a consensus price target of $49.17, signalling upside risk potential of 164.64%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 431.07%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Zai Lab Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is ZLAB or CASI More Risky?
Zai Lab Ltd. has a beta of 0.872, which suggesting that the stock is 12.778% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock ZLAB or CASI?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CASI?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Zai Lab Ltd.'s net income of -$36M is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.51x versus 0.46x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.51x -- $116.2M -$36M CASICASI Pharmaceuticals, Inc.0.46x -- $3.1M -$10.9M
-
Which has Higher Returns ZLAB or CPHI?
China Pharma Holdings, Inc. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of -86.16%. Zai Lab Ltd.'s return on equity of -26.7% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About ZLAB or CPHI?
Zai Lab Ltd. has a consensus price target of $49.17, signalling upside risk potential of 164.64%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Zai Lab Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is ZLAB or CPHI More Risky?
Zai Lab Ltd. has a beta of 0.872, which suggesting that the stock is 12.778% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock ZLAB or CPHI?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CPHI?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Zai Lab Ltd.'s net income of -$36M is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.51x versus 1.06x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.51x -- $116.2M -$36M CPHIChina Pharma Holdings, Inc.1.06x -- $756.2K -$651.5K
-
Which has Higher Returns ZLAB or SVA?
Sinovac Biotech Ltd. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -26.7% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About ZLAB or SVA?
Zai Lab Ltd. has a consensus price target of $49.17, signalling upside risk potential of 164.64%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 SVASinovac Biotech Ltd.0 0 0 -
Is ZLAB or SVA More Risky?
Zai Lab Ltd. has a beta of 0.872, which suggesting that the stock is 12.778% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock ZLAB or SVA?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or SVA?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$36M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.51x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.51x -- $116.2M -$36M SVASinovac Biotech Ltd.1.50x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
